BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

INTRODUCTION: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in combination with gefitinib versus gefitinib single a...

Descripción completa

Detalles Bibliográficos
Autores principales: Karachaliou, Niki, Arrieta, Oscar, Giménez-Capitán, Ana, Aldeguer, Erika, Drozdowskyj, Ana, Chaib, Imane, Reguart, Noemí, Garcia-Campelo, Rosario, Chen, Jing-Hua, Molina-Vila, Miguel Angel, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474244/
https://www.ncbi.nlm.nih.gov/pubmed/34589994
http://dx.doi.org/10.1016/j.jtocrr.2020.100113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474244/
https://www.ncbi.nlm.nih.gov/pubmed/34589994
http://dx.doi.org/10.1016/j.jtocrr.2020.100113

Ejemplares similares